What is the price-to-earnings ratio of Beigene?
The price-earnings ratio of Beigene is currently -1.68.
Beigene P/E 2024
Beigene P/E
-1.68
Ticker
6160.HK
ISIN
KYG1146Y1017
WKN
A144EN
As of Sep 15, 2024, Beigene's P/E ratio was -1.68, a -51.16% change from the -3.44 P/E ratio recorded in the previous year.
The Beigene P/E history
Beigene Aktienanalyse
What does Beigene do?
Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Beigene's P/E Ratio
The Price to Earnings (P/E) Ratio of Beigene is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Beigene's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Beigene is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Beigene’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Beigene stock
How has the price-earnings ratio of Beigene changed compared to last year?
The price-to-earnings ratio of Beigene has increased by -51.16% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Beigene high compared to other companies?
Yes, the price-to-earnings ratio of Beigene is high compared to other companies.
How does an increase in the price-earnings ratio of Beigene affect the company?
An increase in the price-earnings ratio of Beigene would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Beigene affect the company?
A decrease in the price-earnings ratio of Beigene would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Beigene?
Some factors that influence the price-earnings ratio of Beigene are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Beigene pay?
Over the past 12 months, Beigene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beigene is expected to pay a dividend of 0 USD.
What is the dividend yield of Beigene?
The current dividend yield of Beigene is .
When does Beigene pay dividends?
Beigene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Beigene?
Beigene paid dividends every year for the past 0 years.
What is the dividend of Beigene?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Beigene located?
Beigene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Beigene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Beigene from 9/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/15/2024.
When did Beigene pay the last dividend?
The last dividend was paid out on 9/15/2024.
What was the dividend of Beigene in the year 2023?
In the year 2023, Beigene distributed 0 USD as dividends.
In which currency does Beigene pay out the dividend?
The dividends of Beigene are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Beigene
Our stock analysis for Beigene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beigene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
